NCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
Accent Therapeutics
Mirati Therapeutics Inc.
Baylor Research Institute
Pheon Therapeutics
Novartis